Wnt/β-catenin mediated signaling pathways in cancer: recent advances, and applications in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling Pathways

Background:

• The Wnt/β-catenin signaling pathway is integral to numerous cancer hallmarks, including proliferation, stemness, and metastasis.
• Aberrant activation of this pathway is implicated in resistance to chemotherapy, targeted therapy, and immunotherapy.
• Understanding its role is crucial for developing novel anti-cancer strategies.

Purpose of the Study:

• To comprehensively review the Wnt/β-catenin pathway's role in cancer development and therapeutic resistance.
• To analyze the clinical efficacy of combination therapies involving Wnt/β-catenin pathway modulators.
• To highlight the potential of targeting this pathway in precision oncology.

Main Methods:

• Literature review of current research on the Wnt/β-catenin pathway in malignancy.
• Analysis of preclinical and clinical data on targeted inhibitors and combination therapies.
• Synthesis of information on the pathway's involvement in tumor initiation, resistance, and immune regulation.

Main Results:

• The Wnt/β-catenin pathway significantly contributes to oncogenesis, drug resistance, and immune evasion.
• Targeted inhibitors of the Wnt/β-catenin pathway show potential, particularly in combination regimens.
• Synergistic effects observed with combined chemo-, targeted-, and immunotherapy warrant further investigation.

Conclusions:

• Pharmacological modulation of the Wnt/β-catenin pathway presents a promising therapeutic avenue in oncology.
• Combination therapies targeting this pathway offer potential for overcoming treatment resistance.
• Further clinical development is needed to fully realize the therapeutic benefits of Wnt/β-catenin pathway inhibition.